NCT07262229Active, not recruiting
Self-management Digital Intervention to Promote Physical Activity in People Living With COPD
Self-management Digital Intervention to Promote Physical Activity in People Living With Chronic Obstructive Pulmonary Disease: a Pilot Randomized Controlled Trial Study Protocol
Source: ClinicalTrials.gov · Last updated 13 Jul 2026
Brief summary (registry, in English)
The goal of this pilot randomized controlled trial is to evaluate the feasibility, acceptability, and preliminary effects of a theory-based self-management digital intervention (Respir'air BPCO) designed to promote physical activity in patients with Chronic Obstructive Pulmonary Disease (COPD) after completion of a pulmonary rehabilitation program. The main question it aims to answer is: Is the Respir'air BPCO intervention (mobile app) feasible, acceptable, and preliminarily effective in increasing physical activity, enhancing self-management, improving motivation, and quality of life, while reducing dyspnea severity, exacerbations, and hospitalizations, compared with no additional intervention? Researchers will compare an experimental group (receiving the Respir'air BPCO intervention + usual care) to a control group (no additional intervention, only usual care) Participants will: Be assigned either to the control group, receiving no additional intervention beyond usual care (traditional pulmonologist follow-up), or to the experimental group, receiving access to the Respir'air BPCO mobile app in addition to usual care. * Complete baseline assessments immediately after finishing their in-person pulmonary rehabilitation program. * Complete follow-up assessments at 3 months and 6 months after the start of the intervention
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 23 (actual)
- First submitted
- 17 Nov 2025
- Start date
- 22 Jan 2026
- Primary completion date
- Nov 2026
- Lead sponsor
- Institut et Haute Ecole de la Santé la Source
- Diseases
- COPD
- NCT number
- NCT07262229
What you commit to
- Study type: Interventional
- Participants enrolled: 23
- From 22 Jan 2026 to the primary completion date, Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- severe cardiovascular disease confirmed by medical diagnosis;
- recent history of neoplasia or autoimmune disease; other physical activity-limiting clinical condition confirmed by medical diagnosis (e.g. neurological disease);
- other respiratory disease as primary diagnosis; e) inability to read, understand or speak French;
- cognitive impairment diagnosed by the medical team.
Other
- clinical instability confirmed by the team of healthcare professionals;
Who the study is looking for
- a GOLD COPD diagnosis stage 1 to 4, classification B or E;
- admitted electively at Hospital for PR;
- had completed the pulmonary rehabilitation program;
- age over 18 years;
- ability to provide informed consent;
- internet access;
- ownership of a smartphone or tablet;
- self-assessed perceived ease of use of digital devices.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pôle de pneumologie de l'Hôpital de Rolle Coordinator of this site? Confirm its status | Rolle | Switzerland | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.